Eating Disorders Market Spotlight 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Eating Disorders” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the Eating Disorders market,
comprising key marketed and pipeline drugs, clinical trials, upcoming
events, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
revenue forecasts

Key Takeaways

• Worldwide, the report estimates that in 2017, there were approximately
  35.6 million prevalent cases of eating disorders in females aged 10-19
  years, including 3.0 million cases of anorexia nervosa, 11.6 million
  cases of bulimia nervosa, and 14.3 million cases of binge eating
  disorder.
• The author forecasts the number of prevalent cases of eating disorders
  to increase to 38.1 million by 2026. Edgemont’s fluoxetine tablets and
  Takeda’s Vyvanse are the only FDA-approved drugs for eating disorders.
  These drugs are administered via the oral route, with Vyvanse also
  available in an intranasal formulation.
• There are only three industry-sponsored drugs in active clinical
  development for eating disorders, with two drugs in Phase II and one
  in Phase III.
• Therapies in mid-to-late-stage development for eating disorders focus
  on targets such as dopamine reuptake, norepinephrine (noradrenaline)
  reuptake/transporter, opioid receptors, and ghrelin receptor. These
  drugs are administered via the subcutaneous, oral, and intranasal
  routes.
• The only high-impact upcoming event in the eating disorders space is
  topline Phase II trial results for OPNT001. The overall likelihood of
  approval of a Phase I psychiatry-other asset is 11.4%, and the average
  probability a drug advances from Phase III is 80.8%. Drugs, on
  average, take 9.2 years from Phase I to approval, compared to 8.8
  years in the overall psychiatry space.
• There have been only three licensing and asset acquisition deals
  involving eating disorders drugs during 2014-19. The distribution of
  clinical trials across Phase I-IV indicates that the vast majority of
  trials for eating disorders have been in the late phase of
  development, with 91% of trials in Phase III, and only 9% in Phase II.
• The US has a substantial lead in the number of eating disorders
  clinical trials globally, while Germany leads the major EU markets.
• Clinical trial activity in the eating disorders space is dominated by
  completed trials. Takeda has the highest number of completed clinical
  trials for eating disorders, with four trials.
• Takeda leads industry sponsors with the highest number of clinical
  trials for eating disorders.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Psychotherapy

Medications

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Dasotraline for Eating Disorders (July 25, 2018)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/x4d45q

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Mental
Health